Parkinson’s disease psychosis - Pipeline Insight, 2025,
Description
DelveInsight’s, Parkinson’s disease psychosis - Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Parkinson’s disease psychosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Parkinson’s disease psychosis: Overview
Nonmotor symptoms have an important impact on quality of life in PD patients and their caregivers and are largely recognized as such by a growing number of health care providers. Psychosis is recognized as one of the most frequent and disabling nonmotor symptoms in PD with prevalences of 20% up to 70% in advanced stages of the condition. Psychosis in PD patients is mostly arising in patients with a clear sensorium in a chronic setting after a long disease duration and is triggered or enhanced by pharmacological factors. Nonetheless, other recent risk factors have been studied, giving rise to a potential multifactorial underlying aetiology and thus physiopathology. The differentiation between early and late onset psychosis in general, and also specifically in PD, is not currently validated, having some studies randomly set cut-off values at 2–4 years of PD onset to determine early versus late onset psychosis.
""Parkinson’s disease psychosis - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Parkinson’s disease psychosis pipeline landscape is provided which includes the disease overview and Parkinson’s disease psychosis treatment guidelines. The assessment part of the report embraces, in depth Parkinson’s disease psychosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Parkinson’s disease psychosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
Iloperidone: Vanda Pharmaceuticals
Iloperidone belongs to a class of medications for schizophrenia known as atypical antipsychotics. Acceptance of the NDA application confirms that the application is sufficiently complete for FDA review for the treatment of schizophrenia.
Ulotaront: Sumitomo Pharma
Ulotaront (SEP-363856) is a trace amine-associated receptor 1 (TAAR1) agonist with serotonin 5-HT1A agonist activity, jointly developed by Sunovion and PsychoGenics Inc, which is a small-molecule oral agent that does not bind to dopamine D2 or serotonin 5-HT2A receptors. The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for ulotaront for the treatment of schizophrenia in May 2019.
Further product details are provided in the report……..
Parkinson’s disease psychosis: Therapeutic Assessment
This segment of the report provides insights about the Parkinson’s disease psychosis drugs segregated based on following parameters that define the scope of the report, such as:
Parkinson’s disease psychosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Parkinson’s disease psychosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Parkinson’s disease psychosis drugs.
Parkinson’s disease psychosis Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Parkinson’s disease psychosis: Overview
Nonmotor symptoms have an important impact on quality of life in PD patients and their caregivers and are largely recognized as such by a growing number of health care providers. Psychosis is recognized as one of the most frequent and disabling nonmotor symptoms in PD with prevalences of 20% up to 70% in advanced stages of the condition. Psychosis in PD patients is mostly arising in patients with a clear sensorium in a chronic setting after a long disease duration and is triggered or enhanced by pharmacological factors. Nonetheless, other recent risk factors have been studied, giving rise to a potential multifactorial underlying aetiology and thus physiopathology. The differentiation between early and late onset psychosis in general, and also specifically in PD, is not currently validated, having some studies randomly set cut-off values at 2–4 years of PD onset to determine early versus late onset psychosis.
""Parkinson’s disease psychosis - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Parkinson’s disease psychosis pipeline landscape is provided which includes the disease overview and Parkinson’s disease psychosis treatment guidelines. The assessment part of the report embraces, in depth Parkinson’s disease psychosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Parkinson’s disease psychosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence R&D Parkinson’s disease psychosis. The therapies under development are focused on novel approaches to treat/improve Parkinson’s disease psychosis.
Iloperidone: Vanda Pharmaceuticals
Iloperidone belongs to a class of medications for schizophrenia known as atypical antipsychotics. Acceptance of the NDA application confirms that the application is sufficiently complete for FDA review for the treatment of schizophrenia.
Ulotaront: Sumitomo Pharma
Ulotaront (SEP-363856) is a trace amine-associated receptor 1 (TAAR1) agonist with serotonin 5-HT1A agonist activity, jointly developed by Sunovion and PsychoGenics Inc, which is a small-molecule oral agent that does not bind to dopamine D2 or serotonin 5-HT2A receptors. The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for ulotaront for the treatment of schizophrenia in May 2019.
Further product details are provided in the report……..
Parkinson’s disease psychosis: Therapeutic Assessment
This segment of the report provides insights about the Parkinson’s disease psychosis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Parkinson’s disease psychosis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Molecule Type
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Parkinson’s disease psychosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Parkinson’s disease psychosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Parkinson’s disease psychosis drugs.
Parkinson’s disease psychosis Report Insights
- Parkinson’s disease psychosis Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Parkinson’s disease psychosis drugs?
- How many Parkinson’s disease psychosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Parkinson’s disease psychosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Parkinson’s disease psychosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Parkinson’s disease psychosis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Vanda Pharmaceuticals
- Sumitomo Pharma
- Iloperidone
- Ulotaront
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Parkinson’s disease psychosis: Overview
- What is Parkinson’s disease psychosis?
- Types of Parkinson’s disease psychosis
- Causes
- Epidemiology and Risk Factors
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Parkinson’s disease psychosis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Iloperidone: Vanda Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Parkinson’s disease psychosis Key Companies
- Parkinson’s disease psychosis Key Products
- Parkinson’s disease psychosis- Unmet Needs
- Parkinson’s disease psychosis- Market Drivers and Barriers
- Parkinson’s disease psychosis- Future Perspectives and Conclusion
- Parkinson’s disease psychosis Analyst Views
- Parkinson’s disease psychosis Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
